The Danish drugmaker sued Hims in February over compounded versions of the Wegovy weight-loss pill that Hims launched and ...

March 9 (Reuters) - Hims & Hers' shares were up over 40% on Monday, after Novo Nordisk agreed to sell its blockbuster Wegovy ...

By Stine Jacobsen and Maggie Fick COPENHAGEN, March 9 (Reuters) - Novo Nordisk has agreed to sell its blockbuster Wegovy and Ozempic drugs through U.S. telehealth company Hims & Hers' platform, the ...

On Monday morning, Novo Nordisk, the makers of the GLP-1 drug semaglutide (Ozempic and Wegovy), and Hims & Hers Health Inc. jointly announced a ceasefire to their growing hostilities via a new ...

Hims & Hers Health has agreed to stop selling compound versions of Novo Nordisk’s Wegovy and other weight-loss drugs, ending ...

Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a partnership with the Danish drug giant.

Novo Nordisk (NYSE:NVO)and US telehealth company Hims & Hers (NYSE:HIMS) have announced a collaboration that will bring the Danish drugmaker’s weight-loss medications Wegovy and Ozempic to Hims & Hers ...

Novo Nordisk has signed an agreement with Hims & Hers Health that will allow the telehealth provider to offer FDA‑approved versions of Ozempic and Wegovy at self‑pay prices comparable to other digital ...

Novo Nordisk has agreed to sell its blockbuster Wegovy and Ozempic drugs through U.S. telehealth company Hims & Hers' platform, the Danish drugmaker said on Monday, ending a legal dispute that erupted ...

Shares of Hims & Hers jumped as much as 55% Monday after Novo Nordisk announced it is dropping its lawsuit over Ozempic and Wegovy copycat drugs.

Shares of Hims surged as much as 50% in premarket trading, while Novo Nordisk’s Copenhagen-listed stock rose 1.7%. The ...

Telehealth company Hims & Hers on Monday announced a “strategic shift” in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop ...